Submissions
GlyTouCan
Glycan Structure Repository
GlyComb
Glycoconjugate Repository
GlycoPOST
Glycomics MS raw data Repository
UniCarb-DR
Glycomics MS Repository for glycan annotations from GlycoWorkbench
LM-GlycoRepo
Repository for lectin-assisted multimodality data
All Resources
Genes / Proteins / Lipids Glycans / Glycoconjugates Glycomes Pathways / Interactions / Diseases / OrganismsTools
SugarDrawer
GlycanBuilder
Glycan Converters
GlycoMaple
GlycomeAtlas
LM-GlycomeAtlas
GALAXY
MCAW
GlycoSim
GRable
Guidelines
MIRAGE
G61418DU
Summary
- GlyTouCan ID
-
G61418DU
- IUPAC Condensed
- GalNAc(b1-
External Links
- GlyGen
- ChEBI
- PubChem Compound
- PubChem Substance
- The Human Metabolome Database
3D Structures
- GlycoNAVI
- G61418DU
- GlycoShape
- G61418DU
- GLYCAM
- DGalpNAcb1-OH
Organisms
| Organisms | Evidence |
|---|---|
| Cricetulus griseus (Chinese hamster) | |
| Rattus | |
| Escherichia coli |
Taxonomic Hierarchy
GlycoGene Database (GGDB)
G01534TU
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
|---|---|---|---|---|
| B4GALT4 | UDP-Gal |
G61418DU
|
[beta]-1-o-Nitrophenyl | |
| B4GALT3 | UDP-Gal |
G61418DU
|
o-Nitrophenyl-[beta] | |
| B4GALT7 | UDP-Gal |
G61418DU
|
4-D-MethylUmb-[beta] | |
| B4GALT2 | UDP-Gal |
G61418DU
|
o-Nitrophenyl-[beta] | |
| B4GALT2 | UDP-Gal |
G61418DU
|
4-Me-lumbelyl-[beta] |
Pathway
| Pathway Name | Organism |
|---|---|
| E.coli O102 | Escherichia coli |
| E.coli O104 | Escherichia coli |
| E.coli O107 | Escherichia coli |
| E.coli O11 | Escherichia coli |
| E.coli O112ab | Escherichia coli |
| E.coli O112ac | Escherichia coli |
| E.coli O117 | Escherichia coli |
| E.coli O120 | Escherichia coli |
| E.coli O124 | Escherichia coli |
| E.coli O125ab | Escherichia coli |
Sequence Descriptors
- GlycoCT
-
RES 1b:b-dgal-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
- WURCS
- WURCS=2.0/1,1,0/[a2112h-1b_1-5_2*NCC/3=O]/1/
Literature
| PubMed ID | Title | First Author | Publication Date | Source |
|---|---|---|---|---|
| 38839445 | Personalized dosage of Givosiran in acute intermittent porphyria | Garrido Montes M | 2024 Sep 13 |
|
| 39232672 | Role of the GalNAc-galectin pathway in the healing of premature rupture of membranes | Chen JL | 2024 Sep 04 |
|
| 39222205 | RNAi targeting LMAN1-MCFD2 complex promotes anticoagulation in mice | Ma S | 2024 Sep 02 |
|
| 39477529 | Development of bioconjugate-based delivery systems for nucleic acids | Wahane A | 2024 Oct 30 |
|
| 39168524 | Nonclinical Pharmacokinetics Study of OLX702A-075-16, N-Acetylgalactosamine Conjugated Asymmetric Small Interfering RNA (GalNAc-asiRNA) | Ban J | 2024 Oct 16 |
|
| 39379811 | The utilization of N-acetylgalactosamine and its effect on the metabolism of amino acids in Erysipelotrichaceae strain | Zhou M | 2024 Oct 09 |
|
| 39361617 | Aglycone Analysis and Quantitative Tracking of Correlated Terminal Glycan Pair on Spermatozoa | Xu L | 2024 Oct 03 |
|
| 39363243 | Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study | Sardh E | 2024 Oct 03 |
|
| 38992557 | Canadian guidance for diagnosis and management of acute hepatic porphyrias | Francisco Idiaquez J | 2024 Oct |
|
| 39528231 | Improved In Vivo Metabolic Stability and Silencing Efficacy of siRNAs with Phosphorothioate Linkage-Free, GalNAc-Conjugated Sense Strands Containing Morpholino-LNA Modifications | Datta D | 2024 Nov 11 |
|
